Healthcare
Raia Drogasil S.A.(RADLY)
Live Price
Offline$3.27
-17.22% today
1Y Change
+19.22%
Window
Jun 23, 2025 โ Jun 12, 2026
- Market Cap
- $38.34B
- Revenue Growth
- +11.6%
- EPS Growth
- +5.5%
- Dividend Yield
- 1.8%
Coverage: 245 bars ยท Jun 23, 2025 โ Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Raia Drogasil S.A. (RADLY) is a Healthcare stock with a market cap of $38.34B and listed on OTC. The stock last traded around $3.27 and up 19.2% across the available one-year price window (Jun 23, 2025 โ Jun 12, 2026). Baseline metrics include revenue growth of +11.6%, EPS growth of +5.5%, a dividend yield of 1.8%. What stands out right now is revenue +11.6%, EPS +5.5%, free cash flow +60.2% with operating margin 5.9% and ROIC 14.0%. The dividend is present but secondary, with a yield around 1.8%. Valuation is more restrained than many high-expectation growth names at P/E 29.6 and price/sales 0.9. Stock Foundry combines RADLY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+11.6% vs +7.6% peer median
Operating Margin
Below sector median
+5.9% vs +19.4% peer median
P/E
Below sector median
29.6 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 12, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +11.6% and EPS at +5.5%, with operating margin around 5.9%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 1.8%, which matters if the thesis depends on income as much as growth.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +0.1% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 12, 2026 | โ | +0.0% | -14.2% | -17.3% |
2026 Mar 3, 2026 | -16.9% | +2.3% | -0.6% | -2.1% |
2025 Aug 4, 2025 | +41.4% | +0.6% | +15.3% | +20.8% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RADLY
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
RADLY Max Drawdown
-35.28%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for RADLY and SPY.
Company Overview
Raia Drogasil S.A.
Other OTC
Raia Drogasil S.A. engages in the retail sale of medicines, perfumery, personal care and beauty products, cosmetics, dermocosmetics, and specialty medicines in Brazil. As of March 31, 2022, the company operated a network of 2,530 drug stores in 26 Brazilian states. It also markets its goods through telesales and its three call centers in the states of Sรฃo Paulo, Tocantins, and Pernambuco. The company was founded in 1905 and is headquartered in Sรฃo Paulo, Brazil.
- Leadership
- Renato Cepollina Raduan
- IPO Date
- Jul 19, 2016
- Employees
- 66.3k
- Street Address
- Av. Corifeu de Azevedo Marques, 3097
- Mailing
- Sรฃo Paulo, SP, 05.339-900
- Region
- Sรฃo Paulo, SP, BR
- Reporting Currency
- USD
- Investor Line
- 55 11 3769 5678
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 29.6
- EV/EBITDA
- 10.1
- Price/Sales
- 0.9
- Price/Book
- 5.2
Growth
- Revenue
- +11.6%
- EPS
- +5.5%
- Free Cash Flow
- +60.2%
Profitability
- Gross Margin
- 27.0%
- Operating Margin
- 5.9%
- Net Margin
- 2.9%
- ROE
- 18.9%
- ROIC
- 14.0%
Balance Sheet
- Debt/Equity
- 1.21
- Current Ratio
- 1.46
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.